zone" without regard to the extent of thyroidectomy. However the committee built a consensus that total thyroidectomy is encouraged for patients with tumors larger than 4 cm or clinical node metastasis [1] , indicating that tumor size is one of the significant factors for surgeons to decide the extent of thyroidectomy.
Previous studies demonstrated that large tumor size, significant extrathyroid extension, large lymph node metastasis, extranodal tumor extension, and distant metastasis at diagnosis strongly predicted carcinoma recurrence and/or carcinoma death of PTC patients [2] [3] [4] [5] . In contrast, we showed that only 4 out of 2,638 patients (0.2%) with solitary PTC 2 cm or less demonstrating no high-risk features (T1N0M0 in the UICC classification [6] ) developed distant recurrence and only 1 patient died of PTC, [7] . These findings strongly support the recommendations in the guidelines [1] .
Regarding lymph node dissection, the Japanese guidelines recommend routine central node dissection (CND) [1] . The guidelines, however, do not determine the indication of prophylactic modified radical neck dissection (MND). We previously demonstrated A whole-body scan (WBS) using a small amount of radioiodine (3-10 mCi) was performed for 475 patients who underwent total or near-total thyroidectomy, and none of these patients showed abnormal uptakes. Radioiodine ablation therapy using 100 mCi or more was performed for 19 patients. The application of WBS or ablation therapy was decided according to the discretion of the attending physicians.
In this study, we regarded patients as having recurrence only when recurred lesions were detected on imaging studies. Recurrence to the lymph node was evaluated predominantly by ultrasonography. Lymph nodes suspected of metastasis were evaluated using criteria similar to those proposed by Antonelli et al. [10] : firstly, a diameter of 1 cm or more; secondly, a clear hypoechoic pattern or nonhomogeneous pattern, with alternating hypoechoic and hyperechoic areas; thirdly, an irregular cystic appearance; fourthly, the presence of internal calcification; and, lastly, a rounded or bulging shape with an increased antero-posterior diameter. When lymph nodes were suspected of metastasis, we performed ultrasonography-guided fine-needle aspiration biopsy (FNAB) for the nodes and measured the thyroglobulin value in wash-out from the needle used for FNAB [11] to determine whether the nodes were metastatic or reactive. Postoperative follow-up ranged from 6 to 240 months (median follow-up: 126 months). Distant recurrence was detected by imaging studies such as a CT scan, bone scintigraphy, and PET-CT scan during follow-up. To date, 153 patients have shown local recurrence. Forty patients showed recurrence to the remnant thyroid, 118 showed lymph node recurrence, and 9 showed recurrence to other local lesions. Fourteen patients showed more than two local recurrences. Distant recurrence was detected in 33 patients. Recurrence to the lung, bone, and brain was detected in 25, 8, and 1 patient, respectively. One patient showed two or more distant recurrences. To date, 5 patients have died of PTC.
Statistical analyses
The Kaplan-Meier method and log rank test were adopted to analyze time-dependent variables. Multivariate analysis was performed by cox-hazard regression model. A p-value of less than 0.05 was considered significant, and 0.05 < p < 0.1 was regarded as a marginal value. The analysis was performed using Statflex.
that large tumor presence (larger than 3 cm) and significant extrathyroid extension were strong predictors of lymph node recurrence, and recommended prophylactic MND for PTC larger than 3 cm [8] . Sugitani et al. also showed that tumor size larger than 4 cm was a strong indicator of lymph node recurrence [9] . These findings strongly suggest that tumor size significantly correlates with the lymph node recurrence.
In this study, we investigated the prognosis, including recurrence to the remnant thyroid, lymph node and distant organs and cause-specific survival, of PTC patients who do not show distant metastasis, clinical lymph node metastasis or significant extrathyroid extension. The aim of this study is to elucidate whether surgical designs should be changed with tumor size for otherwise low-risk PTC patients.
Patients and methods

Patients
In this study, we enrolled 3,965 patients, who underwent initial surgery between 1990 and 2004 in Kuma Hospital for PTC without clinically apparent lymph node metastasis or distant metastasis on preoperative imaging studies and without significant extrathyroid extension on intraoperative findings. They consisted of 345 males and 3,620 females. The mean age was 50.5 years average. Primary lesions and lymph node metastases were evaluated employing preoperative ultrasonography by trained technicians. We also evaluated the absence of lung metastasis on a CT scan before surgery. Patients demonstrating lesions containing anaplastic carcinoma or other coexisting thyroid malignancies such as follicular carcinoma and medullary carcinoma were excluded from the series.
The extent of thyroidectomy was total (or near total) thyroidectomy for 1,664 patients and more limited thyroidectomy such as lobectomy with isthmectomy and subtotal thyroidectomy for the remaining 2,301 patients. Regarding lymph node dissection, 1,037 patients underwent central node dissection (CND) only and 2,669 underwent prophylactic unilateral or bilateral modified radical neck dissection (MND) as well. The remaining 259 patients did not undergo lymph node dissection.
After surgical treatment, all patients were followed once or twice per year by imaging tests such as ultrasonography, chest roentgenography or computed tomography, and serum thyroglobulin measurement. recurrence-free survival for patients, who underwent limited thyroidectomy. Patients classified as T-2 or T-3 showed significantly higher recurrence rates to the remnant thyroid (p = 0.01818) than T-1 patients. The recurrence rate to the thyroid of T-2 patients did not differ from that of T-3 patients (p = 0.68532).
Lymph node recurrence-free survival in the 2,669 patients who underwent CND and MND is shown in Fig. 1-b. T-2 or T-3 patients were more likely to show lymph node recurrence than T-1 patients (p < 0.00001), although no significant difference could be established between T-2 and T-3 patients (p = 0.11729). Similar results were obtained in the analysis for all patients (data not shown).
Distant recurrence-free survival of patients in the three groups is shown in Fig. 1-c . The survival rates of T-2 or T-3 patients were significantly poorer than those of T-1 patients (p = 0.0011), but the recurrence rates of T-3 patients did not differ from those of T-2 patients (p = 0.1821). Table 3 indicates the 10-year recurrence rates to results
Classification of patients
We classified the 3,965 patients into three groups: T-1, primary lesions measuring 2 cm or less (2,591 patients); T-2, primary lesions measuring 2.1-4 cm (1,123 patients); T-3, primary lesions larger than 4 cm (251 patients). The extents of thyroidectomy and lymph node dissection in each subset are summarized in Tables  1 and 2 . The incidences of total thyroidectomy and MND in T-2 or T-3 patients were higher than those in T-1 patients.
Relationship between recurrence to the remnant thyroid, lymph nodes, and distant organs and the tumor size
As indicated above, recurrence to the remnant thyroid, lymph nodes, and distant organs was detected in 40 patients (2.4% of patients who underwent limited thyroidectomy), 118 patients (3.0%), and 33 patients (0.8%), respectively. Fig. 1-a shows the Kaplan-Meier curves of thyroid the thyroid, lymph nodes, and distant organs, which increased with the tumor size. Especially, lymph node recurrence rates of T-3 patients reached 8.3%, even though they underwent prophylactic MND.
Multivariate analyses for prognostic factors of recurrence to the thyroid, lymph nodes, and distant organs
In order to investigate whether thes tumor size independently affected PTC recurrence, we performed mul- low-risk PTC larger than 2 cm had significantly more biologically aggressive characteristics than that measuring 2 cm or less.
Previously, we showed that solitary T1N0M0 PTC led to an excellent prognosis and total thyroidectomy was not mandatory [5] . In this study, in contrast, we demonstrated that the recurrence rate not only to the thyroid but also to the distant organs of otherwise low-risk PTC significantly increased with the tumor size. However, objectively, the recurrence rate to the distant organs of T-2 and T-3 patients was still low at 1.6% and 3.4%, respectively. Furthermore, the number of patients who died of PTC was very small, and we failed to establish a difference in the carcinoma death rates based on the tumor size. Therefore, it remains unclear whether total thyroidectomy for PTC larger than 2 cm without other high-risk features can improve patients' survival. tivariate analysis for thyroid, lymph node, and distant organ recurrence-free survival rates of patients by analyzing the tumor size (> 2 cm vs. < 2.1 cm) together with other conventional prognostic factors such as tumor multiplicity, gender, and patient age (> 55 yrs vs. < 55 yrs). The UICC classification set the cut-off age at 45 yrs [6] , but in our series, cut-off age at 55 yrs significantly more keenly reflected patients' prognosis [4] . Factors showing an independent prognostic impact (p < 0.1) are described in Tables 4-7 . A tumor size > 2 cm was recognized as an independent prognostic factor of recurrence to the thyroid, lymph node, and distant organs.
Carcinoma death of patients
To date, one patient with T-1 (0.04%), 3 patients with T-2 (0.3%), and one patient with T-3 (0.4%) have died of PTC. Three patients died of distant recurrence and the remaining 2 died of anaplastic transformation of locally recurring lesions. On univariate analysis, the cause-specific survival of patients with T-2 or T-3 did not differ from that of those with T-1 (p = 0.12042). Since the number of patients who died of PTC was small in each subset, further analyses of carcinoma death could not be performed.
discussion
In this study, we investigated the prognosis of PTC patients without high-risk features such as clinical lymph node metastasis, distant metastasis at diagnosis, or significant extrathyroid extension. We showed that 10-year recurrence rates to the thyroid, lymph node, and distant organs of low-risk PTC measuring 2 cm or less (T-1 patients) were very low, at 0.9, 1.9, and 0.4%, respectively. However, these recurrence rates significantly increased with tumor size (Table 3 ). The 10-year thyroid recurrence rates of T-2 and T-3 patients were about 4 and 6 times larger than that of T-1 patients, respectively. The lymph node recurrence rate of T-3 patients was about 4.4 times greater than that of T-1 patients, and reached 8.3%, even though they underwent prophylactic MND. Recurrence rates to distant organs of T-2 and T-3 patients were 4 and 8 times greater than that of T-1 patients, respectively. Furthermore, on multivariate analysis, a tumor size larger than 2 cm was regarded as an independent prognostic factor of recurrence to the thyroid, lymph nodes, and distant organs (Tables 4-7) . We can therefore conclude that otherwise and could not perform a comparative study for these patients. Therefore, it remains unclear whether prophylactic MND improves lymph node recurrence for T-2 and T-3 patients. Indeed, lymph node recurrence rates of T-2 and T-3 patients who underwent prophylactic MND were even a little higher than those of patients who did not undergo prophylactic MND. This is possibly because of selection bias based on preoperative studies e.g., tumors with seemingly benign ultraosnographic findings and/or cytologic findings are unlikely to undergo prophylactic MND. Some kind of prospective study is needed to accurately elucidate this point, but significant elevation of lymph node recurrence rate of T-3 patients up to 8.3% may prompt surgeons to perform prophylactic MND. In summary, we demonstrated that PTC without extrathyroid extension, clinical lymph node metastasis, or distant metastasis larger than 2 cm had the more aggressive biological characteristics and was more likely to show local and distant recurrences than that measuring 2 cm or less. However, since the incidences of distant recurrence and carcinoma death were not high even in large tumors, it is not evident that extensive surgery is mandatory for otherwise low-risk patients with large tumor.
We showed that tumor multiplicity was a moderate prognostic factor for PTC patients [12, 13] . However, in the subset of low-risk patients, this factor significantly predicts recurrence not only to the thyroid but also to distant organs. Therefore, total thyroidectomy for multiple PTC located in one lobe may be considered, although it is not clear whether it improves patients' cause-specific survival rates.
Previously, we demonstrated that a tumor size larger than 3 cm was one of the independent prognostic factors for lymph node recurrence on multivariate analysis [8] . This series included patients having clinical central node metastasis (N1a) and significant extrathyroid extension and all these patients underwent prophylactic MND. In this study, we adopted only patients without any clinical node metastasis or extrathyroid extension and also showed that tumor size was an independent prognostic factor for lymph node recurrence. As shown in Table 3 , the lymph node recurrence rate in the subset of patients who underwent CND and MND did not differ from that in all patients. We performed MND and CND for 58% and CND only for 37% of T-1 patients. This indicates that prophylactic MND is not likely to improve the lymph node recurrence rate of T-1 patients. In contrast, we performed MND for most T-2 and T-3 patients (87% of T-2 patients and 78% of T-3 patients) references
